These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22837211)

  • 41. Protection of mice against Human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein.
    Mekseepralard C; Toms GL; Routledge EG
    J Gen Virol; 2006 May; 87(Pt 5):1267-1273. PubMed ID: 16603529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
    Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.
    Tiwari PM; Vanover D; Lindsay KE; Bawage SS; Kirschman JL; Bhosle S; Lifland AW; Zurla C; Santangelo PJ
    Nat Commun; 2018 Oct; 9(1):3999. PubMed ID: 30275522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS
    Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
    Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
    J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiviral and Immunomodulatory Activity of Silver Nanoparticles in Experimental RSV Infection.
    Morris D; Ansar M; Speshock J; Ivanciuc T; Qu Y; Casola A; Garofalo R
    Viruses; 2019 Aug; 11(8):. PubMed ID: 31398832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
    Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
    Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.
    Plotnicky-Gilquin H; Goetsch L; Huss T; Champion T; Beck A; Haeuw JF; Nguyen TN; Bonnefoy JY; Corvaïa N; Power UF
    J Virol; 1999 Jul; 73(7):5637-45. PubMed ID: 10364313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.
    Krempl C; Murphy BR; Collins PL
    J Virol; 2002 Dec; 76(23):11931-42. PubMed ID: 12414935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.
    Varga SM; Wissinger EL; Braciale TJ
    J Immunol; 2000 Dec; 165(11):6487-95. PubMed ID: 11086089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.